<ENAMEX TYPE="ORGANIZATION">Cytel Corp.</ENAMEX> said it signed a five-year, joint-research agreement valued at more than $30 million with <ENAMEX TYPE="ORGANIZATION">Sandoz AG</ENAMEX> of <ENAMEX TYPE="LOCATION">Basel</ENAMEX>, <ENAMEX TYPE="LOCATION">Switzerland</ENAMEX>, to develop drugs to fight auto-immune diseases and tissue rejection in transplant patients.
As part of the transaction, <ENAMEX TYPE="ORGANIZATION">Sandoz</ENAMEX> purchased less than 20% of closely held <ENAMEX TYPE="ORGANIZATION">Cytel</ENAMEX>, a biotechnology company. Under the agreement, <ENAMEX TYPE="ORGANIZATION">Cytel</ENAMEX> will receive funding over a five-year period to support continuing research, and <ENAMEX TYPE="ORGANIZATION">Sandoz</ENAMEX> will get exclusive world-wide rights to market products developed under the pact. Among the diseases that the immunological drugs may be used to treat are rheumatoid arthritis and insulin-dependent diabetes.
